Collegium Pharmaceutical (NASDAQ:COLL) Stock Bumped Up to “Buy” by Wall Street Zen

Wall Street Zen upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a buy rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other equities analysts have also recently commented on COLL. Barclays cut their price target on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday, August 19th. Oppenheimer initiated coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 price objective on the stock. Jefferies Financial Group restated a “buy” rating and set a $35.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday. Piper Sandler dropped their price objective on shares of Collegium Pharmaceutical from $43.00 to $28.00 and set a “neutral” rating for the company in a report on Friday. Finally, Zacks Research upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “strong-buy” rating in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $44.88.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $24.21 on Friday. The company has a market cap of $788.28 million, a PE ratio of 24.21, a price-to-earnings-growth ratio of 0.75 and a beta of 0.75. The company has a current ratio of 1.13, a quick ratio of 0.84 and a debt-to-equity ratio of 3.65. The stock has a 50-day moving average price of $22.99 and a 200-day moving average price of $32.79. Collegium Pharmaceutical has a 12-month low of $21.43 and a 12-month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 EPS for the quarter, topping the consensus estimate of $1.86 by $0.10. The company had revenue of $216.34 million during the quarter, compared to analyst estimates of $216.03 million. Collegium Pharmaceutical had a return on equity of 85.14% and a net margin of 4.68%. Collegium Pharmaceutical’s revenue was up 67.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.25 earnings per share. As a group, equities analysts forecast that Collegium Pharmaceutical will post 6.42 earnings per share for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds have recently bought and sold shares of the company. Ritholtz Wealth Management increased its holdings in shares of Collegium Pharmaceutical by 150.7% in the third quarter. Ritholtz Wealth Management now owns 20,305 shares of the specialty pharmaceutical company’s stock worth $443,000 after buying an additional 12,205 shares during the period. Illinois Municipal Retirement Fund lifted its stake in shares of Collegium Pharmaceutical by 10.0% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 17,696 shares of the specialty pharmaceutical company’s stock valued at $386,000 after acquiring an additional 1,607 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Collegium Pharmaceutical in the 3rd quarter valued at about $36,000. Profund Advisors LLC lifted its stake in shares of Collegium Pharmaceutical by 621.1% in the 3rd quarter. Profund Advisors LLC now owns 65,710 shares of the specialty pharmaceutical company’s stock valued at $1,434,000 after acquiring an additional 56,597 shares during the last quarter. Finally, Vise Technologies Inc. boosted its holdings in Collegium Pharmaceutical by 154.3% during the 3rd quarter. Vise Technologies Inc. now owns 14,844 shares of the specialty pharmaceutical company’s stock valued at $324,000 after acquiring an additional 9,006 shares during the period.

Collegium Pharmaceutical News Roundup

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Q3 adjusted earnings of $1.96 per share topped consensus estimates, and revenue of $216.3 million narrowly beat expectations. The company reported record quarterly revenue, including JORNAY PM revenue up 24% year over year. Collegium Q3 2026 results
• Positive Sentiment: FY 2026 revenue guidance is $825 million–$855 million, a range whose midpoint is above the $832.9 million consensus estimate. Collegium also announced a $50 million accelerated share repurchase. Collegium Q3 2026 results
• Neutral Sentiment: Needham lowered its price target from $46 to $44 but maintained a Buy rating, indicating continued optimism alongside a more cautious valuation. Needham lowers Collegium price target
• Negative Sentiment: Piper Sandler cut its target sharply, from $43 to $28, and assigned a Neutral rating. The lower valuation outlook could weigh on sentiment despite the target remaining above the referenced share price. Piper Sandler rating
• Negative Sentiment: EPS declined from $2.25 in the year-ago quarter to $1.96, tempering the earnings beat. Collegium Q3 earnings

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.